8/20/2026 1:38:44 PM Best Lawyers Names Three Morris James Attorneys as 2027 "Lawyer of the Year" By Nicholas J. Caggiano Jr. Matthew R. Fogg Gretchen S. Knight Morris James is proud to announce that Best Lawyers of America has named Nick Caggiano, Matt Fogg, and Gretchen Knight as the “Lawyer of...
8/20/2026 12:45:40 PM 32 Morris James Attorneys Earn "Best Lawyers" Recognition; 9 Listed as "Ones to Watch" By Morris James LLP Morris James is proud to announce that The Best Lawyers in America has recognized 41 of our attorneys for 2027. Spanning each of our five...
7/9/2026 12:59:38 PM Delaware Victims Injured in Maryland Boat Explosion: Legal Questions After a Fueling Incident By Matthew R. Fogg Ross C. Karsnitz By: Matt Fogg and Ross Karsnitz A Fourth of July boating incident near Chesapeake City, Maryland, has raised serious safety and legal...
6/12/2026 3:00:38 PM Michael Owen Moderates Panel on Recent Delaware Trial Trends at DTLA Annual Convention By Michael G. Owen Partner Michael Owen, Chair of the firm's Personal Injury Practice Group and a Delaware Trial Lawyers Association (DTLA) Committee...
5/29/2026 8:19:08 PM What Percentage Do Personal Injury Lawyers Take? By Ashley C. Curran W. Christopher Componovo If you’ve been injured and are considering hiring a lawyer, one of your first questions is probably: what is this going to cost me? It’s...
5/27/2026 6:07:08 PM Statute of Limitations: Is It Too Late to File a Dupixent Claim? By Keith E. Donovan Matthew R. Fogg By Morris James Mass Torts Attorneys Matthew R. Fogg and Keith E. Donovan If you or a loved one was diagnosed with cutaneous T-cell...
4/10/2026 5:12:38 PM Morris James Files Nearly 30 Cases in the Depo-Provera Multidistrict Litigation By Keith E. Donovan Matthew R. Fogg Morris James has filed 29 cases in the Depo-Provera multidistrict litigation, adding to the growing body of claims alleging that women...
4/3/2026 6:25:08 PM Morris James Investigating Olympus Scope Infection Claims By Keith E. Donovan Matthew R. Fogg Morris James LLP is now accepting cases on behalf of patients who developed serious infections after an endoscopy, gastroscopy,...
4/1/2026 2:27:37 PM Dupixent for Children: What Parents Should Ask Their Doctor About Cancer Risk By Keith E. Donovan Matthew R. Fogg Dupixent (dupilumab) has been a genuine breakthrough for many families. For children with moderate-to-severe eczema, asthma, and other...
3/20/2026 8:33:37 PM Morris James Investigating GLP-1 Drug-Related Vision Loss Claims By Keith E. Donovan Matthew R. Fogg Morris James LLP is now accepting cases on behalf of patients who suffered serious vision loss after taking GLP-1 medications such as...
3/20/2026 6:43:07 PM FDA Class I Recall of FreeStyle Libre 3 Sensors: Practical Steps and Legal Considerations By Matthew R. Fogg Keith E. Donovan By: Keith Donovan and Matthew Fogg Key Takeaways The FDA has identified a Class I recall (its most serious type) involving certain...
3/19/2026 5:06:37 PM FDA Expands Dupixent for Children Amid Growing CTCL Concerns By Keith E. Donovan Matthew R. Fogg By: Keith Donovan and Matthew Fogg The FDA has expanded approval of Dupixent® (dupilumab) for children aged six and older with allergic...
2/26/2026 9:23:07 PM Dupixent Lawsuits: How the Masking Effect May Hide Cutaneous T-Cell Lymphoma By Matthew R. Fogg Keith E. Donovan For many people living with severe eczema, Dupixent feels like a breakthrough. After years of painful flare-ups, constant itching, and...
2/13/2026 12:59:37 PM What Dupixent Users Should Know in 2026: A Patient Advocacy Guide By Keith E. Donovan Matthew R. Fogg If you or someone you love uses Dupixent, you may have recently seen television ads or online headlines linking the medication to rare...
12/23/2025 3:38:37 PM Injured by a Prescription Drug? What You Need to Know About Pharmaceutical Lawsuits and Failure to Warn Claims By Keith E. Donovan Matthew R. Fogg When we take prescription medications, we trust that they will help us feel better, not leave us with devastating side effects we were...
12/17/2025 12:39:38 PM FDA Updates Depo-Provera Label to Include Brain Tumor Risk — Key Litigation Development By Keith E. Donovan Matthew R. Fogg The U.S. Food and Drug Administration (FDA) has approved a significant update to the prescribing information for Depo-Provera, adding a...